Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 1,623 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: normal saline solution placebo Clear all

Conditions: Cerebral Palsy
Interventions: Cord Blood Infusion, Intravenous Sham; Biological
Lead sponsor: Augusta University; Other
Eligibility: 1 Year to 12 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2019
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Chronic Gout
Interventions: SEL-212 low-dose, SEL-212 high-dose, Placebo; Drug · Other
Lead sponsor: Swedish Orphan Biovitrum; Industry
Eligibility: 19 Years to 80 Years
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 30
States / cities: Clearwater, Florida • DeBary, Florida • Hialeah, Florida + 24 more

Conditions: Respiratory Failure
Interventions: Hypertonic saline (3%), Placebo (0.9% saline); Drug
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: Up to 18 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Rotator Cuff Tear
Interventions: 0.5% bupivacaine, Normal Saline; Drug
Lead sponsor: Orlando Health, Inc.; Other
Eligibility: 18 Years to 90 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Severe Preeclampsia
Interventions: AMAG-423 (digoxin immune fab), Placebo; Biological · Other
Lead sponsor: AMAG Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 16
States / cities: Mobile, Alabama • Kansas City, Kansas • Louisville, Kentucky + 12 more

Conditions: Surgery, Infection
Interventions: Polymyxin B in Normal Saline, Placebo: Normal Saline; Drug · Other
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 88 Years
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: HIV Infections
Interventions: VSV-Indiana HIV gag vaccine, Placebo injection (normal saline); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2011
U.S. locations: 4
States / cities: San Francisco, California • Decatur, Georgia • Philadelphia, Pennsylvania + 1 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Placebo, Glucose-dependent Insulinotropic Polypeptide (GIP), Xenin-25, Glucose-dependent Insulinotropic Polypeptide plus Xenin-25; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Post Operative Pain
Interventions: 0.25% bupivicaine will be injected at the study port site prior to incision, Saline will be injected at the study port site prior to incision, Saline will be in injected into the port site prior to closure, 0.25% bupivicaine will be injected into the port site prior to closure; Drug
Lead sponsor: Stony Brook University; Other
Eligibility: 21 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Pain
Interventions: bupivacaine liposome injectable suspension, Placebo; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 14
States / cities: Mobile, Alabama • Englewood, Colorado • Miami, Florida + 9 more

Conditions: Osteoarthritis, Knee
Interventions: Amniotic Fluid, Saline Placebo; Other
Lead sponsor: MiMedx Group, Inc.; Industry
Eligibility: 30 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 4
States / cities: Birmingham, Alabama • Atlanta, Georgia • Des Plaines, Illinois + 1 more

Conditions: Sleep Restriction
Interventions: Ketoconazole Pill, Ganirelix, Dexamethasone, Dexamethasone Injection, Cosyntropin Injectable Product, Recombinant Human Luteinizing Hormone, Hydrocortisone Injection, Gonadorelin, Corticorelin, Placebo oral capsule, Saline Solution, Saline Solution for Injection; Drug
Lead sponsor: Peter y. Liu; Other
Eligibility: 22 Years to 45 Years · Male only
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Torrance, California

Conditions: Cardiovascular Disease
Interventions: FEIBA, Normal Saline; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Pelvic Organ Prolapse
Interventions: pudendal block, no pudendal block; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Iron Deficiency Anemia
Interventions: Ferumoxytol, Saline, Ferrous sulfate tablets, Vitamin C; Drug
Lead sponsor: Auerbach Hematology Oncology Associates P C; Other
Eligibility: 18 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cystic Fibrosis
Interventions: MRT5005, Normal saline; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 16
States / cities: Birmingham, Alabama • Denver, Colorado • Gainesville, Florida + 13 more

Conditions: Schwannomatosis, Schwannomas, Pain, Chronic
Interventions: Siltuximab, Erenumab-Aooe, Siltuximab Matching Placebo, Erenumab-Aooe Matching Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: COVID-19, SARS-CoV-2 Infection
Interventions: CoTend-BXBB (SARS2-30404), CoTend-s3BXBB (SARS2-17032), Placebo; Biological
Lead sponsor: Kara Chew; Other
Eligibility: 40 Years to 64 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 2
States / cities: Los Angeles, California • San Francisco, California

Conditions: Pain
Interventions: Lidocaine, Placebo (normal saline); Drug · Other
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Dermatomyositis
Interventions: IMO-8400 Dose Group 1, IMO-8400 Dose Group 2, Placebo; Drug
Lead sponsor: Idera Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 17
States / cities: Birmingham, Alabama • Phoenix, Arizona • Irvine, California + 14 more

Conditions: Graft Rejection
Interventions: Placebo, C1 Esterase Inhibitor (Human); Biological
Lead sponsor: Shire; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 4
States / cities: Los Angeles, California • Baltimore, Maryland • Minneapolis, Minnesota + 1 more

Conditions: Osteoarthritis, Knee, Meniscus Tear, Meniscus; Degeneration, Synovitis
Interventions: Zilretta Injectable Product or Placebo; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 40 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts • Cleveland, Ohio

Conditions: Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Interventions: NTLA-2001, Placebo; Biological · Drug
Lead sponsor: Intellia Therapeutics; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 39
States / cities: Tucson, Arizona • Los Angeles, California • Palo Alto, California + 30 more

Conditions: Influenza
Interventions: NasoVAX; Biological
Lead sponsor: Altimmune, Inc.; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Rockville, Maryland

Search by objective public record fields.

Safety and Effectiveness of Cord Blood Stem Cell Infusion for the Treatment of Cerebral Palsy in Children

A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy II

Nebulized Hypertonic Saline for Mechanically Ventilated Children

Post-Op Rotator Cuff Pain Study With Subacromial Bupivacaine Infusion

Study of the Efficacy and Safety of AMAG-423 (Digoxin Immune Fab) in Antepartum Subjects With Severe Preeclampsia

Antibiotic Irrigation for Pancreatoduodenectomy

Evaluating the Safety of and Immune Response to the VSV-Indiana HIV Vaccine in Healthy, HIV-Uninfected Adults

Xenin-25: Novel Regulator of Insulin Secretion and Beta-cell Function

Study to Compare Reduction in Pain After Surgery With and Without Local Anesthesia During Laparoscopy

Efficacy, Safety, and Pharmacokinetics of Femoral Nerve Block With EXPAREL in Total Knee Arthroplasty

Protocol for the Clinical Evaluation of Lyophilized Amniotic Fluid in the Treatment of Knee Osteoarthritis

Hormonal Mechanisms of Sleep Restriction - Axis Study

FEIBA and Use of Blood Products in Cardiac Surgery

Use of Pre-Emptive Pudendal Nerve Block for Pelvic Reconstructive Surgery

Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient

Study to Evaluate the Safety & Tolerability of MRT5005 Administered by Nebulization in Adults With Cystic Fibrosis

Screening Trial for Pain Relief in Schwannomatosis (STARFISH)

A Phase 1/2A, Randomized Study of a T Follicular Helper (TFH)-Targeting Genetic Vaccine Strategy Designed to Induce Broad, Durable Immune Responses

Effect of Perioperative Intravenous Lidocaine on Postoperative Quality of Recovery in Patients Undergoing Spine Surgery

Trial of IMO-8400 in Adult Patients With Dermatomyositis

A Pilot Study to Evaluate the Use of C1 Esterase Inhibitor (Human) in Patients With Acute Antibody-Mediated Rejection

Corticosteroid Meniscectomy Randomized Trial

MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX